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A B S T R A C T
Desmoid-type ﬁbromatosis, also called desmoid tumor, is a locally aggressive myoﬁbroblastic neoplasm that
usually arises in deep soft tissue with signiﬁcant potential for local recurrence. It displays an unpredictable
clinical course.
β-Catenin, the genetic key player of desmoid tumors shows nuclear accumulation due to mutations that
prevent its degradation leading to activation of Wnt signaling and myoﬁbroblastic cell proliferation. The cor-
responding hot spot mutations are located in exon 3 of the CTNNB1 gene or alternatively, in the APC tumor
suppressor gene, most often as a germline mutation.
Multifocal desmoid tumors are very rare and clinical characteristics are poorly understood. Here we present
six sporadic and one familial case of multifocal desmoid tumors.
Four female and three male patients, aged between 7 and 30 years (mean 18.4 years) were identiﬁed in a
cohort of 1392 cases. Tumors were located in (distal) extremities, thorax, breast, abdominal wall, shoulder, and
neck. Four cases showed a CTNNB1 mutation and one an APC germline mutation. In two sporadic cases no
CTNNB1 mutation was identiﬁed. Four patients showed (multiple) recurrences and one patient was lost to
follow-up.
In conclusion, multifocal desmoid tumors are a very rare disease and may occur in sporadic cases that are
characterized by recurrent CTNNB1 mutations. However, the underlying pathogenesis of multifocal desmoid
tumors remains poorly understood with often aggressive clinical behavior and challenging therapeutical man-
agement.
1. Introduction
Desmoid-type ﬁbromatosis, or desmoid tumor, is a locally ag-
gressive, inﬁltrative growing myoﬁbroblastic lesion with unpredictable
clinical behavior. It may originate at any part of the body with
extremities, abdominal wall and mesentery being the most common
sites [1]. The peak incidence is in the third decade [1].
Desmoid tumors arise sporadically in approximately 90% of the
cases with the remaining 10% being familial [1]. Dysregulation of the
Wnt signaling pathway is characteristic in both settings with β-catenin
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being the key player. In sporadic cases, the most common activating
mutations are located in exon 3 of the CTNNB1 gene (chr 3p22.1)
coding for β-catenin. Alternatively, in the remaining sporadic cases and
the familial cases that occur in the context of Gardner syndrome (a form
of familial adenomatous polyposis), there is a somatic or germline in-
activating mutation or allelic deletion in the APC tumor suppressor
gene (5q22.2) [1-4]. Both mechanisms lead to stabilization of β-catenin
with cytoplasmatic and subsequently nuclear accumulation. Within the
nucleus, β-catenin acts as a transcription factor regulating cell pro-
liferation of myoﬁbroblastic cells [1,5,6].
In the recent years, a paradigm shift in terms of treatment mod-
alities has taken place for desmoids tumors and the overall management
is increasingly complex. It has been shown that invasive treatment
should be used with caution because of the potential of recurrence,
irrespective of the margin status [5,7-9]. In this context, mutational
analysis of CTNNB1 can give prognostic information, where the hot spot
mutation p.Ser45Phe (p.S45F), has been proposed as a possible marker
for recurrence [10-12].
Single cases of multifocal desmoid tumors have been described [13-
15], but their genetic and clinical characteristics are not well under-
stood. We describe herein a series of multifocal desmoid tumors and
their mutational status to pay attention on these rare cases.
2. Material and methods
The cases were collected from the authors' ﬁles and the nationwide
network and registry of histopathology and cytopathology in the
Netherlands. Clinical data and follow-up were obtained from the pa-
tient records. The study was performed in accordance with the Code of
Conduct of the Federation of Medical Scientiﬁc Societies in the
Netherlands.
In all cases the tissue was ﬁxed in 4% buﬀered formalin and em-
bedded in paraﬃn; 2–4 μm thick sections were stained with hematox-
ylin and eosin and immunohistochemically by the labelled Streptavidin
Biotin technique using a commercially available antibody against β-
catenin (BD Biosciences, clone 14, dilution 1:100). Appropriate positive
and negative controls were used throughout.
DNA was isolated from formalin-ﬁxed, paraﬃn-embedded material
(without decalciﬁcation) by proteinase K digestion and the crude DNA
extract was used in a standard PCR. The hot spot region for CTNNB1
was ampliﬁed using primers: 5′-ATGGCCATGGAACCAGACAGA-3′ and
5′-GCTACTTGTTCTTGAGTGAAGGACTG-3′. The region most frequently
mutated in APC (NM_000038.5: amino acids 1200–1580) was ampliﬁed
using the following primer pairs: 1) 5′-CAGATATTCCTTCATCACAGA
AAC-3′ and 5′-GGAGTATCTTCTACACAATAAGTCTG-3′, 2) 5′-GCCACT
TGCAAAGTTTCTTC-3′ and 5′-TCACAGGATCTTCAGCTGACCT-3′, 3)
5′-TCAGACGACACAGGAAGCAGAT-3′ and 5′-TTTTGGGTGTCTGAGCA
CCACT-3′, 4) 5′-AGCCAGGCACAAAGCTGTTGAA-3′ and 5′-TGTCCAG
GGCTATCTGGAAGATCA-3′, 5) 5′-ACCATGCAGTGGAATGGTAAG
TGG-3′ and 5′-TGGAAGAACCTGGACCCTCTGAA-3′, 6) 5′-TGGACCTA
AGCAAGCTGCAGTA-3′ and 5′-CTGCTCTGATTCTGTTTCATTCCCAT
TGT-3′, 7) 5′-TCTGAGCCTCGATGAGCCATTT-3′ and 5′-ACGTGATGAC
TTTGTTGGCATGG-3′. All PCR products were analyzed by ﬂuorescent
di-deoxysequencing.
Table 1
Clinical data and mutation status.
Case nr. Sex (m/
f)
Age of ﬁrst presentation
(y)




1 m 13 Knee and gluteus Resection, RT c.121A > Ga
p.Thr41Ala
No
2 f 24 Breasts (left+ right) Resection No mutation found No
3 m 17 Upper leg and hallux Resection c.134C > T;
p.Ser45Phe
Upper leg (10) and hallux
(63)
4 f 27 Upper leg and lower leg Resection c.121A > G
p.Thr41Ala
Lost to follow-up
5 m 11 Upper leg and hallux Resection c.121A > Ga
p.Thr41Ala
Hallux (36)
6 f 30 Abdominal wall, thorax, back,
shoulder, neck
Resection, Lucrin, LHRH antagonist,
Tamoxifen, RT
No mutation found Multiple, in all locations
(6)
7 f 7 Ankle, back and lower leg Resection APC mutationa
(Gardner)
Ankle (7, 18 and 28), back
(10)
M, male; f, female.
a Mutation in two lesions tested.
Fig. 1. Coronal contrast-enhanced spinecho T1-weighted MR-images with fat
saturation of the buttock and proximal posterior side of the right lower leg
showed an irregular lesion compatible with desmoid tumor. The extension of
the lesion is displayed between the white arrows (Case 1).
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3. Results
Out of 1392 cases, seven cases with multifocal desmoid tumors were
selected; clinicopathological and genetic results are summarized in
Table 1. Of the seven patients four were female and three were male.
Age ranged from 7 to 30 years (mean 18.4 years). Lesions were located
in knee and gluteus (1), thigh and lower leg (1), thigh and foot (2),
trunk, shoulder and neck (1), lower leg and back (1) and both mammae
(1). In all cases neoplasms were resected. (Multiple) local recurrences
were reported in 4 patients. Two patients experienced no recurrences so
far and one patient was lost to follow-up. One patient was additionally
treated with systemic (Lucrin, LHRH antagonist, Tamoxifen) and ra-
diation therapy and one patient with radiotherapy only.
Coronal contrast-enhanced spinecho T1-weighted MR-images with
fat saturation of the buttock and proximal (Fig. 1) and distal (Fig. 2)
posterior side of the right lower leg in Case 1 showed an irregular lesion
compatible with desmoid tumor. The extension of the lesion is dis-
played between the white arrows.
Histologically, all cases showed classical features of desmoid tumor
according to the current WHO classiﬁcation of tumors of soft tissue and
bone [16]: lesions consisted of long fascicles myoﬁbroblastic cells with
monomorphous elongated nuclei. There was a variable collagenous
background with sometimes coarse collagen bundles. Myxoid features
were sometimes focally present. Small vessels were found parallel to the
fascicles of tumor cells. A perivascular edema was often seen (Fig. 3).
Immunohistochemically, nuclear expression of beta catenin was
detected in all cases (Fig. 4).
By Sanger sequencing, mutations in CTNNB1 were found in four
cases with p.(Thr41Ala) being the most frequent (n=3) (Fig. 5). One
case harbored a p.(Ser45Phe) mutation. Two sporadic cases showed no
CTNNB1 mutation and one case was known with a germline APC mu-
tation.
In case 1, 5 and 7 two lesions each were tested and yielded the same
mutation.
4. Discussion
It has been shown that desmoid-type ﬁbromatosis derives from
mesenchymal progenitor cells (MPC) harboring a mutation in the
CTNNB1 gene with consecutive β-catenin stabilization [6]. The nuclear
accumulated protein binds to transducing beta-like protein leading to
expression of several Wnt/APC/β-catenin pathway target genes in-
cluding proliferation-stimulating factors such as S100A4 resulting in
growth of myoﬁbroblastic cells [1].
The capacity of circulation of mesenchymal progenitor cells (MPCs)
including CTNNB1 mutated MPCs could explain multifocal develop-
ment of this tumor type [6]. This is reﬂected by the occurrence of the
same mutation in the diﬀerent lesions tested per patient in our series
(n=3). However, cases of multifocal desmoid tumors are exceedingly
rare and mostly known in patients with germline APC mutations and a
subsequent second somatic hit [4]. Diﬀerent CTNNB1 mutations in
multifocal diseases are also reported hypothesizing that genetic al-
terations can take place in diﬀerent stages of myoﬁbroblastic progenitor
cells [15].
Our small series consist of mainly sporadic multifocal cases and
shows that clinical management is naturally more diﬃcult than in the
common unilocular cases. In terms of age, localization and mutational
status the herein described cases are similar to solitary cases re-
presenting young aged patients with lesions mainly in the lower
Fig. 2. Coronal contrast-enhanced spinecho T1-weighted MR-images with fat
saturation of the knee/distal posterior side of the right lower leg showed the
second desmoid tumor. The extension of the neoplasm is displayed by the white
arrows (Case 1).
Fig. 3. Classical features of desmoid tumor showing long fascicles of mono-
morphic elongated myoﬁbroblasts were seen in all cases.
Fig. 4. Immunohistochemistry showed nuclear accumulation of β-catenin in all
cases.
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extremities [1].
The course of desmoid tumors is unpredictable, as spontaneous re-
gression, long-lasting stable disease and disease progression can occur.
Reliable and validated predictive factors are lacking [1]. In several
studies it has been shown that mutational status of the hot spots in-
ﬂuences prognosis with p.Ser45Phe (p.S45F) CTNNB1 mutation being a
risk factor for local recurrence after curative intended surgery [10-12].
Nevertheless this is not conﬁrmed by others [17,18].
In terms of mutational status and associated prognosis of multifocal
lesions, we cannot draw any conclusion since our series is very small
and one case is known with an APC germline mutation. However,
p.Thr41Ala (p.T41A) is the most common genetic event in our series.
In our cases, recurrences were common (4/7 cases) and surgical
intervention limited in some cases due to additional mutilation.
Multimodality treatment including systemic (targeted) therapy
could be of special interest [9,19] and identiﬁcation of reliable clinical
or genomic biomarkers predicting behavior of (multifocal) desmoid
tumors is needed to facilitate a more patient tailored approach for
successful management.
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